The RUNX1/RUNX1T1 Network: Translating Insights into Therapeutic Options

Fusion genes and their underlying chromosomal alterations are a hallmark of acute myeloid leukaemia (AML). They are particularly prevalent in paediatric AML where more than 50% of all cases harbour a fusion gene [1, 2]. As fusion genes predict clinical outcome they are used for patient stratification in the WHO 2016 classification of AML [3]. More than 60% of all rearrangements found in pediatric AML target only five different protein complexes: the core binding factor (CBF), the epigenetic regulator MLL, the nuclear receptor RARA and the nuclear pore component NUP98 [1, 2].

Source: Experimental Hematology - November 16, 2020 Category: Hematology Authors: Laura E. Swart, Olaf Heidenreich Tags: Review Source Type: research